Article

Fundus autofluorescence shows RPE atrophy in birdshot chorioretinopathy

Fundus autofluorescence can demonstrate retinal pigment epithelial (RPE) atrophy in patients with birdshot chorioretinopathy, according to Hideki Koizumi, MD. RPE atrophy is difficult to visualize with other imaging techniques.

Fundus autofluorescence can demonstrate retinal pigment epithelial (RPE) atrophy in patients with birdshot chorioretinopathy, according to Hideki Koizumi, MD. RPE atrophy is difficult to visualize with other imaging techniques.

Dr. Koizumi and colleagues, from Kyoto Prefectural University of Medicine, Kyoto, Japan, conducted a study that included 16 eyes of eight Caucasian patients aged 35 to 73 years. The duration of the birdshot chorioretinopathy, which is characterized by hypopigmented spots on the choroid, in these patients ranged from 1 month to 19 years. The patients were evaluated using color and autofluorescence photography and optical coherence tomography.

Of the 16 eyes, 11 eyes of six patients had RPE atrophy as evidenced by hypoautofluorescent regions. Some of the hypoautofluorescent areas corresponded to the hypopigmented birdshot lesions, but the others did not necessarily correspond, which suggested that both the choroid and the RPE can be independently affected, he explained. Eight eyes (50%) of four patients showed linear hypoautofluorescent streaks along the retinal vessels, most of which corresponded to visible changes at the level of the RPE. Placoid hypoautofluorescence in the macula was seen in six eyes of three patients and was significantly correlated with a best-corrected visual acuity of 20/50 or less (p

"Monitoring the RPE atrophy with fundus autofluorescence may be important for the evaluation and management of birdshot chorioretinopathy," Dr. Koizumi concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.